Drug Overview
The medication known as anti ag7 antibody drug conjugate abgn 107 (also referred to as ABGN-107) is an investigational, next-generation targeted therapy designed to treat aggressive gastrointestinal and other solid tumors. It is an Antibody-Drug Conjugate (ADC), a class of “smart drugs” that act like a molecular guided missile. The drug is engineered to seek out a specific carbohydrate antigen, known as AG7, which is highly expressed on the surface of various cancer cells but rarely found on healthy tissues.
Developed by Abgenomics International, ABGN-107 combines a high-affinity monoclonal antibody with a potent cell-killing agent. Its primary mission is to deliver a lethal payload directly into the heart of the tumor, maximizing cancer cell death while minimizing the “collateral damage” typically associated with traditional chemotherapy.
- Generic Name: Anti-AG7 antibody-drug conjugate ABGN-107.
- Drug Class: Antibody-Drug Conjugate (ADC).
- Target: AG7 (a Lewis-type carbohydrate antigen).
- Route of Administration: Intravenous (IV) infusion.
- FDA Approval Status: Investigational. As of 2026, ABGN-107 is not FDA-approved and is currently undergoing Phase I/II clinical trials to establish its safety and preliminary effectiveness.
What Is It and How Does It Work? (Mechanism of Action)
The AG7 Target
The AG7 antigen is a specific sugar structure (carbohydrate) found on the proteins of cancer cells. It is especially prevalent in “adenocarcinomas”—cancers that start in glandular tissues—such as those of the stomach, colon, and pancreas.
Molecular Level Mechanisms
- Selective Binding: After being infused into the bloodstream, the antibody portion of ABGN-107 circulates until it encounters a cell displaying the AG7 antigen. It locks onto the target with high precision.
- Internalization: Once bound to the surface, the cancer cell “swallows” the ADC through a process called receptor-mediated endocytosis, bringing the drug inside the cell.
- Lysosomal Release: Inside the cell, ABGN-107 is transported to the lysosome (the cell’s “stomach”). Here, enzymes break down the linker, releasing the toxic payload into the cell’s interior (cytoplasm).
- Microtubule Disruption: The released toxin interferes with the cell’s microtubules the internal “scaffolding” required for cell division. This causes the cancer cell to freeze during division, leading to cell cycle arrest and eventually apoptosis (programmed cell death).
- Bystander Effect: In some cases, the toxin can leak out of the dying cancer cell to kill neighboring tumor cells, even if they don’t express the AG7 antigen.
FDA Approved Clinical Indications
There are currently no FDA-approved indications for ABGN-107.
The drug is strictly available through participation in clinical trials (such as NCT02908113). It is being investigated for the following conditions:
Oncological Uses (Investigational):
- Gastric (Stomach) Cancer: Specifically for patients with advanced or metastatic disease who have failed standard therapies.
- Colorectal Cancer: Targeting AG7-positive tumors in the large intestine.
- Pancreatic Cancer: Investigating efficacy in one of the most difficult-to-treat solid tumors.
- Biliary Tract Cancers: Including cancers of the bile ducts and gallbladder.
Dosage and Administration Protocols
In clinical trial settings, ABGN-107 is administered by medical professionals in a hospital or specialized infusion center.
| Treatment Detail | Protocol Specification |
| Standard Schedule | Administered once every 2 weeks (14-day cycle) or every 4 weeks |
| Route | Intravenous (IV) Infusion |
| Infusion Time | Typically administered over 30 to 90 minutes |
| Dosing Basis | Doses are calculated based on the patient’s body weight (mg/kg) |
| Dose Adjustments | Based on the monitoring of liver function and blood cell counts |
Clinical Efficacy and Research Results
Clinical data through 2025 and 2026 has focused on determining the “Maximum Tolerated Dose” (MTD) and identifying the types of cancer most responsive to ABGN-107.
- Antitumor Activity: Early-phase results have shown encouraging signs of “stable disease” and “partial responses” in patients with heavily pre-treated gastric and colorectal cancers.
- Biomarker Correlation: Research indicates that patients whose tumors show “high AG7 expression” on biopsy are significantly more likely to respond to the treatment.
- Durable Responses: In a subset of pancreatic cancer patients, the drug has shown the ability to halt tumor growth for several months longer than expected with current second-line therapies.
Safety Profile and Side Effects
As a targeted therapy, ABGN-107 is designed to be less toxic than traditional chemotherapy, but it still carries risks related to its chemical payload.
Common Side Effects (>10%):
- Fatigue: A general sense of tiredness or lack of energy.
- Nausea: Usually manageable with standard anti-nausea medications.
- Decreased Appetite.
- Diarrhea.
Serious Adverse Events:
- Hepatotoxicity: Elevation of liver enzymes (ALT/AST), requiring regular blood monitoring.
- Myelosuppression: A drop in white blood cell counts (neutropenia), which can increase the risk of infection.
- Infusion Reactions: Fever or chills occurring during or shortly after the IV infusion.
- Management Strategies: To prevent infusion reactions, patients are often given “pre-medications” such as antihistamines and acetaminophen. Liver function is checked before every dose.
Research Areas
In the realm of Stem Cell and Regenerative Medicine, ABGN-107 is being used to study “Cancer Stem Cells” (CSCs). Some gastrointestinal tumors contain rare stem-like cells that are resistant to normal chemotherapy and cause the cancer to “regenerate” or return after treatment. Researchers are investigating whether the AG7 antigen is present on these CSCs. If ABGN-107 can successfully target and destroy these “seed cells,” it could prevent cancer recurrence and lead to longer-lasting remissions.
Patient Management and Practical Recommendations
Pre-treatment Tests to be Performed:
- AG7 Antigen Screening: A biopsy of the tumor is required to confirm that AG7 is present.
- Baseline Liver Function Tests (LFTs): To ensure the liver is healthy enough to process the drug.
- Complete Blood Count (CBC): To check starting immune levels.
Precautions During Treatment:
- Liver Health: Avoid alcohol and certain over-the-counter medications (like high-dose acetaminophen) that can stress the liver while on this therapy.
- Infection Monitoring: Report any fever over 100.4°F (38°C) to your oncology team immediately.
“Do’s and Don’ts” List:
- DO keep a diary of your symptoms to discuss with your doctor at each infusion.
- DO stay well-hydrated, especially in the 24 hours following the infusion.
- DON’T ignore persistent diarrhea, as it can lead to dangerous dehydration.
- DON’T skip scheduled blood tests; these are the “safety net” used to catch side effects before they become serious.
Legal Disclaimer
The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. ABGN-107 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.
